$RSPI
RespireRx Pharmaceuticals Inc. Stock $rspi

$rspi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223012542 Filed on April 17, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$367.6K	$191.7K	$1.150M
YoY Change	73.92%	-47.03%	-38.08%
% of Gross Profit
Research & Development	$98.22K	$29.23K	$429.5K
YoY Change	-30.39%	-80.73%	-38.82%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$465.9K	$221.0K	$1.579M
YoY Change	32.17%	-56.98%	-38.29%
Operating Profit	-$465.9K		-$1.579M
YoY Change	32.17%		-38.29%
Interest Expense	$225.0K	-$168.7K	$603.8K
YoY Change	-276.08%	-35.11%	-193.14%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$681.0K	-$289.7K	-$2.103M
YoY Change	41.8%	-62.56%	-33.14%
Income Tax
% Of Pretax Income
Net Earnings	-$681.0K	-$639.6K	-$2.103M
YoY Change	41.8%	-17.33%	-33.14%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.04
Diluted Earnings Per Share	$0.00	-$0.01	-$0.04
COMMON SHARES
Basic Shares Outstanding	144.3M shares	119.6M shares	111.3M shares
Diluted Shares Outstanding	168.2M shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.320K	$90.00	$90.00
YoY Change	36500.0%	-93.57%	-93.57%
Cash & Equivalents	$7.321K	$88.00	$90.00
Short-Term Investments
Other Short-Term Assets	$134.0K	$22.69K	$22.69K
YoY Change	72.42%	-89.06%	-89.06%
Inventory
Prepaid Expenses	$77.19K	$22.69K
Receivables
Other Receivables
Total Short-Term Assets	$141.3K	$22.78K	$22.78K
YoY Change	81.8%	-89.09%	-89.09%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$141.3K	$22.78K	$22.78K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$141.3K	$22.78K	$22.78K
YoY Change	81.8%	-89.09%	-89.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.890M	$5.724M	$5.724M
YoY Change	5.42%	9.33%	9.33%
Accrued Expenses	$3.447M	$3.296M	$3.296M
YoY Change	16.09%	26.35%	26.35%
Deferred Revenue
YoY Change
Short-Term Debt	$2.873M	$2.709M	$2.709M
YoY Change	18.75%	30.35%	30.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.21M	$11.73M	$11.73M
YoY Change	11.25%	18.21%	18.21%
LONG-TERM LIABILITIES
Long-Term Debt	$74.00K	$174.0K	$174.0K
YoY Change	-68.38%	-40.82%	-40.82%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$74.00K	$174.0K	$174.0K
YoY Change	-68.38%	-40.82%	-40.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.21M	$11.73M	$11.73M
Total Long-Term Liabilities	$74.00K	$174.0K	$174.0K
Total Liabilities	$12.28M	$11.90M	$11.90M
YoY Change	9.59%	16.51%	16.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$177.2M	-$176.1M
YoY Change	1.07%	1.21%
Common Stock	$220.7K	$125.5K
YoY Change	88.55%	28.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.14M	-$11.88M	-$11.88M
YoY Change
Total Liabilities & Shareholders Equity	$141.3K	$22.78K	$22.78K
YoY Change	81.8%	-89.09%	-89.09%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$681.0K	-$639.6K	-$2.103M
YoY Change	41.8%	-17.33%	-33.14%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$128.6K	$11.15K	-$143.9K
YoY Change	107.42%	-107.17%	-84.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	135.8K	-11.12K	$142.6K
YoY Change	119.82%	-107.11%	-85.1%
NET CHANGE
Cash From Operating Activities	-128.6K	11.15K	-$143.9K
Cash From Investing Activities
Cash From Financing Activities	135.8K	-11.12K	$142.6K
Net Change In Cash	7.180K	30.00	-$1.310K
YoY Change	-3221.74%	-96.47%	-99.86%
FREE CASH FLOW
Cash From Operating Activities	-$128.6K	$11.15K	-$143.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000849636
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	RSPI	Gain On Warrant Exchange GainOnWarrantExchange		usd
CY2021	us-gaap	Stockholders Equity Note Spinoff Transaction StockholdersEquityNoteSpinoffTransaction		usd
CY2021	RSPI	Stock Issued During Period Value Issuance Of Common Stock Upon Cashless Warrant Exercise StockIssuedDuringPeriodValueIssuanceOfCommonStockUponCashlessWarrantExercise		usd
CY2022	RSPI	Stock Issued During Period Value Issuance Of Common Stock Upon Cashless Warrant Exercise StockIssuedDuringPeriodValueIssuanceOfCommonStockUponCashlessWarrantExercise		usd
CY2021	RSPI	Equitybased Conversion Fees EquitybasedConversionFees		usd
CY2021	RSPI	Deferred Financing Costs DeferredFinancingCosts		usd
CY2022	RSPI	Gain On Warrant Exchange GainOnWarrantExchange		usd
CY2021	RSPI	Gain On Settlement Or Modification Of Debt Or Other Liabilities GainOnSettlementOrModificationOfDebtOrOtherLiabilities		usd
CY2021	RSPI	Loss On Note Modification LossOnNoteModification		usd
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	RSPI	Deferred Offering Costs Applied Against Equity Proceeds DeferredOfferingCostsAppliedAgainstEquityProceeds		usd
CY2022	RSPI	Accounts Payable And Accrued Expenses Extinguished With Common Stock Options AccountsPayableAndAccruedExpensesExtinguishedWithCommonStockOptions		usd
CY2022	RSPI	Increase In Principal Amount Of Convertible Note IncreaseInPrincipalAmountOfConvertibleNote		usd
CY2021	RSPI	Conversion Of Accounts Payable To Officer Notes Payable To Officer ConversionOfAccountsPayableToOfficerNotesPayableToOfficer		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q4	RSPI	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts		usd
CY2021Q4	RSPI	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2022Q4	RSPI	Deferred Tax Liabilities Deferred Expense Stock Options Issued Connection With Payment Of Debt DeferredTaxLiabilitiesDeferredExpenseStockOptionsIssuedConnectionWithPaymentOfDebt		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	1-16467
CY2022	dei	Entity Registrant Name EntityRegistrantName	RespireRx Pharmaceuticals Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0303583
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	126 Valley Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite C
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Glen Rock
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07452
CY2022	dei	City Area Code CityAreaCode	(201)
CY2022	dei	Local Phone Number LocalPhoneNumber	444-4947
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	360000	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	144326672	shares
CY2022	dei	Auditor Firm AuditorFirmId	200
CY2022	dei	Auditor Name AuditorName	HASKELL & WHITE LLP
CY2022	dei	Auditor Location AuditorLocation	Irvine, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1398	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	177883	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	22693	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29456	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	22781	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	208737	usd
CY2022Q4	us-gaap	Assets Assets	22781	usd
CY2021Q4	us-gaap	Assets Assets	208737	usd
CY2022Q4	RSPI	Accounts Payable And Accrued Expenses To Related Party AccountsPayableAndAccruedExpensesToRelatedParty	725618	usd
CY2021Q4	RSPI	Accounts Payable And Accrued Expenses To Related Party AccountsPayableAndAccruedExpensesToRelatedParty	483195	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5724390	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5235767	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3296008	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2608708	usd
CY2022Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	58934	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1258315	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	790153	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	833463	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	837104	usd
CY2022Q4	RSPI	Notesand Advances Payableto Officers NotesandAdvancesPayabletoOfficers	375334	usd
CY2021Q4	RSPI	Notesand Advances Payableto Officers NotesandAdvancesPayabletoOfficers	230356	usd
CY2022Q4	RSPI	Notes Payable Former Officers Current NotesPayableFormerOfficersCurrent	225744	usd
CY2021Q4	RSPI	Notes Payable Former Officers Current NotesPayableFormerOfficersCurrent	205222	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	15847	usd
CY2021Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	15185	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11729101	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9922495	usd
CY2022Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	294000	usd
CY2021Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	0	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Noncurrent AccountsPayableRelatedPartiesNoncurrent	174000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Noncurrent AccountsPayableRelatedPartiesNoncurrent	294000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	174000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	294000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	11903101	usd
CY2021Q4	us-gaap	Liabilities Liabilities	10216495	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	21703	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	21703	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125544276	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125544276	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97894276	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97894276	shares
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	10 for 1 reverse stock split basis which occurred on January 5, 2021
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	125544	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	97894	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164030289	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	163827781	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176057856	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173955136	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11880320	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10007758	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22781	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	208737	usd
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	351600	usd
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	1104226	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1149823	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1857085	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	339600	usd
CY2021	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	448625	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	429532	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	702043	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1579355	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2559128	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1579355	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2559128	usd
CY2021	RSPI	Gain On Warrant Exchange GainOnWarrantExchange	1099	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	100000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	62548	usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-71161	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	13536	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	12289	usd
CY2022	us-gaap	Interest Expense InterestExpense	603818	usd
CY2021	us-gaap	Interest Expense InterestExpense	724769	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	51614	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	75410	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2102720	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3144840	usd
CY2022	RSPI	Deemed Dividend Associated With Most Favored Nation Provisions Of Convertible Notes DeemedDividendAssociatedWithMostFavoredNationProvisionsOfConvertibleNotes	1870273	usd
CY2021	RSPI	Deemed Dividend Associated With Most Favored Nation Provisions Of Convertible Notes DeemedDividendAssociatedWithMostFavoredNationProvisionsOfConvertibleNotes	378042	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3972993	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3522882	usd
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	10 for 1 reverse stock split basis which occurred on January 5, 2021
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	10 for 1 reverse stock split basis which occurred on January 5, 2021
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111322742	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88347206	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-8063320	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117299	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	52609	usd
CY2021	RSPI	Stock Issued During Period Value Issuance Of Note Commitment Shares And Beneficial Conversion Feature StockIssuedDuringPeriodValueIssuanceOfNoteCommitmentSharesAndBeneficialConversionFeature	70488	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	332510	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	58750	usd
CY2021	RSPI	Gain On Warrant Exchange GainOnWarrantExchange	1099	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	675063	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3144840	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10007758	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13158	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	217000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2102720	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11880320	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2102720	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3144840	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	390911	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	552787	usd
CY2022	RSPI	Equitybased Conversion Fees EquitybasedConversionFees	2000	usd
CY2022	RSPI	Deferred Financing Costs DeferredFinancingCosts	177883	usd
CY2021	RSPI	Gain On Warrant Exchange GainOnWarrantExchange	1099	usd
CY2022	RSPI	Gain On Settlement Or Modification Of Debt Or Other Liabilities GainOnSettlementOrModificationOfDebtOrOtherLiabilities	100000	usd
CY2022	RSPI	Loss On Note Modification LossOnNoteModification	-71161	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	51614	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	75410	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-102614	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2197	usd
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	177883	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	482282	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	605820	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	687300	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1067899	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	196278	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	155607	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-143905	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-956172	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	120000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	823869	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117299	usd
CY2022	RSPI	Proceeds From Insurance Financings Net Of Repayments ProceedsFromInsuranceFinancingsNetOfRepayments	-95188	usd
CY2021	RSPI	Proceeds From Insurance Financings Net Of Repayments ProceedsFromInsuranceFinancingsNetOfRepayments	10577	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	117783	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	142595	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	956745	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1310	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	573	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1398	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	825	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1398	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	12720	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	8653	usd
CY2022	RSPI	Issuance Of Common Stock In Exchange For Extinguishment Of Convertible Notes Payable Inclusive Of Interest And Conversion Fees Paid With Commons Stock Upon Principal Repayment Of Convertible Notes Payable IssuanceOfCommonStockInExchangeForExtinguishmentOfConvertibleNotesPayableInclusiveOfInterestAndConversionFeesPaidWithCommonsStockUponPrincipalRepaymentOfConvertibleNotesPayable	217000	usd
CY2021	RSPI	Issuance Of Common Stock In Exchange For Extinguishment Of Convertible Notes Payable Inclusive Of Interest And Conversion Fees Paid With Commons Stock Upon Principal Repayment Of Convertible Notes Payable IssuanceOfCommonStockInExchangeForExtinguishmentOfConvertibleNotesPayableInclusiveOfInterestAndConversionFeesPaidWithCommonsStockUponPrincipalRepaymentOfConvertibleNotesPayable	332510	usd
CY2022	RSPI	Issuance Of Common Stock As Commitment Shares Upon Issuance Of Convertible Notes IssuanceOfCommonStockAsCommitmentSharesUponIssuanceOfConvertibleNotes	13158	usd
CY2021	RSPI	Issuance Of Common Stock As Commitment Shares Upon Issuance Of Convertible Notes IssuanceOfCommonStockAsCommitmentSharesUponIssuanceOfConvertibleNotes	70488	usd
CY2022	RSPI	Cashless Warrant Exercises CashlessWarrantExercises	5950	usd
CY2021	RSPI	Cashless Warrant Exercises CashlessWarrantExercises	2845	usd
CY2021	RSPI	Deferred Offering Costs Applied Against Equity Proceeds DeferredOfferingCostsAppliedAgainstEquityProceeds	52609	usd
CY2021	RSPI	Accounts Payable And Accrued Expenses Extinguished With Common Stock Options AccountsPayableAndAccruedExpensesExtinguishedWithCommonStockOptions	35000	usd
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	120000	usd
CY2021	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	294000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1870273	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	323096	usd
CY2022	us-gaap	Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset	13334	usd
CY2021	us-gaap	Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset	351967	usd
CY2021	RSPI	Increase In Principal Amount Of Convertible Note IncreaseInPrincipalAmountOfConvertibleNote	13000	usd
CY2022	RSPI	Conversion Of Accounts Payable To Officer Notes Payable To Officer ConversionOfAccountsPayableToOfficerNotesPayableToOfficer	13659	usd
CY2021Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a ten to one reverse-stock split of its common stock
CY2021Q4	RSPI	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Value Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantValueOrRight	16200	usd
CY2022Q4	RSPI	Adjusted Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights AdjustedClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12363640	shares
CY2022Q4	RSPI	Adjusted Class Of Warrant Or Right Exercise Price Of Warrants Or Rights AdjustedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.0015
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	419683183	shares
CY2022Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.0074
CY2022	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M10D
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2102720	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3144840	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-143905	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-956172	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11880320	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	904439	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zeVz2EUJRDZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zOfEmIVu700h">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	RSPI	Reverse Stock Split Policy Textblock ReverseStockSplitPolicyTextblock	<p id="xdx_84C_ecustom--ReverseStockSplitPolicyTextblock_zzyC1Rnxj6S8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zorvdTQM76Yg">Reverse Stock Split on January 5, 2021</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2021, <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20210105_z58VfzTlYwG4">the Company effected a ten to one reverse-stock split of its common stock</span>. Every ten shares of the “old” common stock was exchanged for one “new” share of common stock rounded down to the nearest whole share with any fractional shares of common stock paid to the stockholder in cash. Option and warrant issuances prior to January 5, 2021 have also been proportionately adjusted by dividing the number of shares into which such options and warrants may exercise by ten and multiplying the exercise price by ten.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0124	pure
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zeLrvGbour1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zlxvnGrYfVlk">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.8933	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q4	RSPI	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Value Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantValueOrRight	590932	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	380568	shares
CY2022Q4	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesExercisable	0	shares
CY2021Q4	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesExercisable	0	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	39500	usd
CY2021	RSPI	Accounts Payable And Accrued Expenses Extinguished With Common Stock Options AccountsPayableAndAccruedExpensesExtinguishedWithCommonStockOptions	35000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	54250	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend	<p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_zIPhCAtmvJ9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z8RitkqSYMk2">Patent Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and are charged to general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1972995	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	378042	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1070224348	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	116900219	shares
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zfdOMbK2ot5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z3j4UaGA7Uk3">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain comparative figures in 2022 have been reclassified to conform to the current year’s presentation. These reclassifications were immaterial, both individually and in the aggregate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2012Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2013-06-25
CY2021Q2	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	10000	usd
CY2021Q3	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	75000	usd
CY2022Q1	us-gaap	Payments For Fees PaymentsForFees	415	usd
CY2022	RSPI	Attorneys Fees And Cost AttorneysFeesAndCost	47937	usd
CY2022Q4	RSPI	Accured Interest AccuredInterest	39552	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	RSPI	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	3504424	shares
CY2022Q4	RSPI	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	3504424	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125544276	shares
CY2020Q3	us-gaap	Convertible Debt ConvertibleDebt	600000	usd
CY2021	RSPI	Gain Loss On Exchange Of Convertible Notes GainLossOnExchangeOfConvertibleNotes	1099	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	59420298	shares
CY2021Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.0718
CY2021	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M29D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	370280035	shares
CY2022	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued	0.0015
CY2022	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Issued Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm	P4Y3M7D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2317150	shares
CY2022	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired	0.5121
CY2022	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged	-1062500	shares
CY2022	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExchanged	0.0700
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	7700000	shares
CY2022	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised	0.0015
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	419683183	shares
CY2022Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.0074
CY2022	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M10D
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0023
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28809352	shares
CY2020Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.1528
CY2020	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P2Y7M20D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	39182841	shares
CY2021	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued	0.0200
CY2021	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Issued Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsIssuedWeightedAverageRemainingContractualTerm	P4Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	9395	shares
CY2021	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired	74.8891
CY2021	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged	-1062500	shares
CY2021	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExchanged	0.0700
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	7500000	shares
CY2021	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised	0.0200
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	59420298	shares
CY2021Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.0718
CY2021	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M29D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9306368	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.095
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M12D
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.000
CY2022	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantedWeightedAverageRemainingContractualTerm2	P0Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	107012	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	44.29
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9199356	shares
CY2022Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1	0.592
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M26D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	9199356	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	9199356	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7165215	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.225
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2194444	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.019
CY2021	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantedWeightedAverageRemainingContractualTerm2	P4Y11M23D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	53291	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	73.305
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9306368	shares
CY2021Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1	1.095
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M12D
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	9306368	shares
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	9306368	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125544276	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125544276	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9199356	shares
CY2022	RSPI	Debt Conversion Shares Issuable DebtConversionSharesIssuable	641341808	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	419683183	shares
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1760000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2906000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3911000	usd
CY2021Q4	RSPI	Deferred Tax Liabilities Deferred Expense Stock Options Issued Connection With Payment Of Debt DeferredTaxLiabilitiesDeferredExpenseStockOptionsIssuedConnectionWithPaymentOfDebt	202000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22577000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19671000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	482000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	733000	usd
CY2022Q4	RSPI	Deferred Tax Asset Liabilities Accrued Interest Due To Related Party DeferredTaxAssetLiabilitiesAccruedInterestDueToRelatedParty	222000	usd
CY2021Q4	RSPI	Deferred Tax Asset Liabilities Accrued Interest Due To Related Party DeferredTaxAssetLiabilitiesAccruedInterestDueToRelatedParty	186000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25041000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27609000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25041000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27609000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.090	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.300	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.220	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021Q3	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	75000	usd
CY2021Q3	RSPI	Agreement Expiration Date AgreementExpirationDate	2022-06-30
CY2022	RSPI	Commercial Sale Of Product CommercialSaleOfProduct	350000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	591333	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	591333	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	536333	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	10000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	15000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	15000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	15000	usd

Files In Submission

Name	View Source	Status
rspi-20221231_lab.xml	Edgar Link	unprocessable
rspi-20221231_pre.xml	Edgar Link	unprocessable
0001493152-23-012542-index-headers.html	Edgar Link	pending
0001493152-23-012542-index.html	Edgar Link	pending
0001493152-23-012542.txt	Edgar Link	pending
0001493152-23-012542-xbrl.zip	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rspi-20221231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rspi-20221231_def.xml	Edgar Link	unprocessable
rspi-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSPI
RespireRx Pharmaceuticals Inc. Stock $rspi

2023 Q2 Form 10-K Financial Statement

#000149315223012542 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSPI RespireRx Pharmaceuticals Inc. Stock $rspi

2023 Q2 Form 10-K Financial Statement

#000149315223012542 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSPI
RespireRx Pharmaceuticals Inc. Stock $rspi